Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Sees Large Increase in Short Interest

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) saw a significant growth in short interest in the month of June. As of June 15th, there was short interest totalling 4,380,000 shares, a growth of 6.6% from the May 31st total of 4,110,000 shares. Based on an average daily volume of 594,800 shares, the days-to-cover ratio is currently 7.4 days. Approximately 17.8% of the company’s shares are short sold.

Insider Buying and Selling at Arcturus Therapeutics

In other Arcturus Therapeutics news, COO Pad Chivukula sold 26,000 shares of Arcturus Therapeutics stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $40.01, for a total value of $1,040,260.00. Following the sale, the chief operating officer now owns 447,448 shares in the company, valued at $17,902,394.48. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 13.80% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of ARCT. Russell Investments Group Ltd. acquired a new position in Arcturus Therapeutics during the 1st quarter worth $40,000. AJOVista LLC acquired a new position in shares of Arcturus Therapeutics during the 4th quarter worth about $65,000. Quest Partners LLC acquired a new position in shares of Arcturus Therapeutics during the 4th quarter worth about $67,000. Public Employees Retirement System of Ohio acquired a new position in shares of Arcturus Therapeutics during the 4th quarter worth about $89,000. Finally, China Universal Asset Management Co. Ltd. boosted its position in shares of Arcturus Therapeutics by 352.3% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 3,089 shares of the biotechnology company’s stock worth $97,000 after acquiring an additional 2,406 shares in the last quarter. 94.54% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the company. Canaccord Genuity Group reduced their target price on Arcturus Therapeutics from $87.00 to $86.00 and set a “buy” rating on the stock in a research report on Friday, May 10th. HC Wainwright reiterated a “buy” rating and issued a $60.00 price objective on shares of Arcturus Therapeutics in a report on Tuesday. Finally, William Blair reiterated an “outperform” rating on shares of Arcturus Therapeutics in a report on Thursday, May 23rd. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat, Arcturus Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $64.86.

Arcturus Therapeutics Price Performance

ARCT opened at $21.93 on Friday. Arcturus Therapeutics has a 12 month low of $17.52 and a 12 month high of $45.00. The stock has a market capitalization of $590.57 million, a price-to-earnings ratio of -5.61 and a beta of 2.64. The business has a fifty day moving average price of $29.81 and a 200 day moving average price of $32.42.

Arcturus Therapeutics (NASDAQ:ARCT) last released its earnings results on Wednesday, May 8th. The biotechnology company reported ($1.00) EPS for the quarter, topping the consensus estimate of ($1.17) by $0.17. Arcturus Therapeutics had a negative return on equity of 37.61% and a negative net margin of 81.59%. The firm had revenue of $38.01 million during the quarter, compared to analysts’ expectations of $22.12 million. On average, research analysts anticipate that Arcturus Therapeutics will post -4.39 earnings per share for the current year.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.